Stay In The Know

Join The Discord & Study Up With The Foundation Video Series https://tradejournal.co/connect

News

Live Stream

Timestamps in video description

https://youtu.be/vFbbf5lKuWs

Research / Recap / Additional Video

https://www.reddit.com/r/thinkorswim/comments/lavry2/tos_still_owes_me_600_anyone_else/

Watchlist

70% 310mc 30so

February 2, 2021 06:40 AM ET (BZ Newswire) -- M&A

BlackRock-managed funds and accounts lead investment in Astra to launch a new generation of space services to improve life on Earth

Astra, the fastest privately-funded company in history to demonstrate orbital launch capability, and Holicity Inc. (NASDAQ:HOL) ("Holicity"), a special purpose acquisition company ("SPAC"), today announced a definitive business combination agreement that will result in Astra becoming a publicly-traded company. The transaction reflects an implied pro forma enterprise value for Astra of approximately $2.1 billion. Upon closing, the transaction is expected to provide up to $500 million in cash proceeds, including up to $300 million of cash held in the trust account of Holicity and an upsized $200 million PIPE led by funds and accounts managed by BlackRock.

"This transaction takes us a step closer to our mission of improving life on Earth from space by fully funding our plan to provide daily access to low Earth orbit from anywhere on the planet," said Chris Kemp, Founder, Chairman, and CEO of Astra.

"I have long believed space provides an unmatched opportunity to benefit and enrich society," said Craig McCaw, Chairman, and CEO of Holicity. "Astra's space platform will further improve our communications, help us protect our planet, and unleash entrepreneurs to launch a new generation of services to enhance our lives."

80%  350mc 55f

HOUSTON, Feb. 2, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ:MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma. This appears to be the result of the high cytotoxic potential of Annamycin previously demonstrated in vitro against sarcoma cells in combination with its high uptake by the lungs where the tumors in this study are localized.  Computerized tomography (CT) scans demonstrated that animals treated with Annamycin exhibited significant suppression of tumor growth and not a single death was observed in the treated animals, whereas significant tumor burden contributed to the rapid death of 90% of untreated animals. While the study continues, as of day 130,  the survival rate for animals treated with Annamycin was 100%, compared with only 10% for untreated animals.

60% 45mc 62f

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS), through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the Company has entered into an exclusive option agreement to evaluate a preclinical potential COVID-19 vaccine developed at the Julius-Maximilians-University Wuerzburg (the “University”), one of Germany’s leading research and teaching universities. The vaccine technology developed at the University uses a typhoid fever vaccine as a carrier strain and has the potential to be an orally active COVID-19 (SARS-CoV-2) live-attenuated bacterial vaccine.

60% 15mc 13f

30% 180mc 22f

No new besides pending lawsuit.

Free Gap Scanner + Win 2 Free Stocks 🎉 (Each Up To $1600) 👉👉 http://enzlo.com/webull

Best Savings Account Ever! 😍 Win $10 Million - Use Code: WINKLER 👉👉 http://enzlo.com/save

Watchlist 👉👉 https://tradejournal.co/post/tuesday-pre-market-top-gainers-402/